Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


Ebola in 2015 - end of the line for a killer?

14 December 2014, 15:31

Paris - After decades making brief, murderous forays from central Africa's forests, Ebola erupted into a global emergency in 2014, yet its success could spell its downfall as scientists scramble to relegate it to a footnote of medical history.

From a single infection in impoverished West Africa, the epidemic swept into bustling cities, killed thousands and unleashed a wave of fear in far-off Europe and America.

From a standing start in August, the World Health Organisation (WHO) gave the green light for the use of experimental treatments, and with vaccines being developed there are already a dozen leading candidates for anti-Ebola medication.

"People are very hopeful that we may be seeing some early results towards the end of the first quarter [of 2015] with some of these therapeutics," said Michael Kurilla of the US National Institute of Allergy and Infectious Diseases (Niaid).

Also Read: Christmas cancelled in Sierra Leone
"If these things do prove to be efficacious, we may be able to approve some of them and then have cures or specific licensed treatments for Ebola."

First diagnosed in the former Zaire in 1976, the virus killed 1 590 people in 24 outbreaks until 2012, with a death rate of up to 90% of the infected in the worst cases, the victims often suffering massive internal and external bleeding.

But it inflicted few deaths compared with diseases like Aids or malaria and only broke out in poor, remote areas, with drug research limited and driven mainly by the US government's bio-terror fears.

"There has been little incentive to date for the private sector to invest in and commercialise products that might only ever be needed in the poorest parts of the world," said Sharon Lewin, director of the University of Melbourne's Doherty Institute for Infection and Immunity.

End of indifference

Since the beginning of the year, Ebola has killed more than 6,500 people, spilling from Guinea into its west African neighbours before causing the first-ever domestic infections outside of Africa, two in the United States and one in Spain.

As governments closed borders and screened air passengers, indifference towards the epidemic evaporated and pharmaceutical companies began a race to develop treatments, vaccines and faster, mobile diagnostic tests.

Among the vaccines, cAd3-ZEBOV recently reported good results from early Phase I safety tests on a group of healthy volunteers in the United States.

"We are manufacturing approximately 20 000 additional doses of the vaccine candidate so that if the ongoing Phase I trials are successful, we can begin the next phases", hopefully "early in 2015", pharma company GlaxoSmithKline told AFP.

Also Read: Ebola death toll climbs to 6,583
Among the treatments, frontrunner ZMapp has already been given to a number of stricken medical personnel, though its efficacy is not proven and doses have run out.

Broad-spectrum antiviral drugs are also being tested, and trials will start soon with therapies based on the blood or plasma of Ebola survivors.

Scientists believe the epidemic will be under control within a year in any case, but warn that the virus will continue to survive in an animal "reservoir", possibly fruit bats, from where it jumps every so often to humans in close contact.

And while hopes are riding on a pharmaceutical breakthrough some experts say improvements in medical infrastructure and infection control measures such as isolating patients, contact tracing and education provide the best answers.

"Outbreaks that have occurred in the past, they have been stopped without vaccine," said David Heymann, a virologist and head of the Centre on Global Health Security.



Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Nigeria @ 56: Words to my green f...

A leader’s job is not to dictate, but rather to be respected, admired and be a trustee, of the land we love, with so much potential, a land which should be freer than free. Its still a long way to fufilling our destiny! Read more...

Submitted by
Isaac Asabor263
Recession: An opportunity for Nig...

The recession should be seen as an opportunity for the country’s promotion as long as we all collectively conduct ourselves in a patriotic manner, writes Isaac Asabor.  Read more...

Submitted by
Black and White

We want to imitate the whites in everything because we are ignorant of our inherent originality and content. We spend all our Naira to acquire his inventions because we so oblivious of our natural endowments that we allow him have it for free. Read more...

Submitted by
Nate Nat
Adamawa State University Mubi: A ...

ADSU integrity forum has accused the Sunday Joshua Wugira, a lawyer, of adopting unorthodox tactics by abusing his privilege by attacking the integrity of ADSU Vice Chancellor Dr. Moses Zira Zaruwa, writes a News24 reader. Read more...

Submitted by
Abdulsalam Jubril
My Country Nigeria (Part One)

Poetry by Abdulsalam Jubril.

Submitted by
Abdulsalam Jubril
Recession, dearth in leadership a...

Every leader has the opportunity to become great and making himself immortal in the lives and hearts of people for generations to come. Will Mr. President seize this opportunity?, questions Abdulsalam Jubril. Read more...